GSK plc, GSK, GSK.L, GS71.DE, FDA Calendar, PDUFA Date

Company Name	GSK plc GSK, GSK.L, GS71.DE
Drug Name	Tebipenem HBr (NDA)
Event Name	FDA decision on tebipenem HBr as oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis
Event Date	06/18/2026
Outcome Date
Outcome	pending
Drug Status	If approved, tebipenem HBr could be the first oral carbapenem antibiotic for patients in the US who suffer from cUTIs
Rival Drugs
Market Potential
Other Approvals
News

Return to FDA Calendar

Slide Shows